- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$6.29 BnMarket Estimate, 2026
$7.72 BnMarket Forecast, 2034
$39.49 BnCAGR, 2026–2034
22.64%North America Biochips Market Report: Size, Share, Trends & Forecast (2026–2034)
- Market Scope: Comprehensive regional industry evaluation covering DNA chips, lab-on-a-chip technologies, protein chips, end-user segments (hospitals, biopharma, research institutes), and country-level developments across the U.S. and Canada.
- Market Valuation: Valued at USD 6.29 billion in 2025, estimated at USD 7.72 billion in 2026, and projected to reach USD 39.49 billion by 2034, registering a rapid compound annual growth rate (CAGR) of 22.64% from 2026 to 2034.
- Primary Growth Drivers: A rising geriatric demographic necessitating rapid diagnostic tools, high volumes of local drug discovery pipelines, increasing cancer research initiatives, and strong government funding supporting genomic innovations.
North America Biochips Market Segment Metrics (2026–2034)
| Category | Leading Segment / Position | Fastest-Growing Segment |
|---|---|---|
| By Product / Technology | DNA Chips (dominates through extensive SNP genotyping, genomics, and gene expression workflows) | Lab-On-A-Chip & Proteomics (expanding via point-of-care diagnostics and high-throughput screening needs) |
| By End User | Biotechnology & Pharmaceutical Companies (major buyers deploying biochips for large-scale drug development) | Hospitals & Diagnostic Centers (accelerating adoption due to rising oncology and clinical screening demands) |
| By Country | The United States (leads the regional market through advanced R&D infrastructure, MIT research, and federal funding) | Canada (securing steady growth driven by government-backed cancer research and precision medicine initiatives) |
Major North American Biochips Market Players & Industry Structure
Market Structure: A highly modern, innovation-focused ecosystem characterized by high product costs offset by robust venture capital, federal grants, and fierce corporate competition centered around cost-effective chip design.
Key Companies: Agilent Technologies Inc., Fluidigm Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., GE Healthcare, Cepheid Inc., Illumina Inc., and Thermo Fisher Scientific Inc.
North America Biochips Market Size
The North America Biochips Market is projected to grow from USD 6.29 billion in 2025 to USD 7.72 billion in 2026 and reach USD 39.49 billion by 2034, registering a CAGR of 22.64% during the forecast period from 2026 to 2034.
North America accounted for the largest market share in the global biochips market in 2023. There is a rise in the geriatric population in North America, and thus there is a need for quick methods for diagnosing diseases. The number of drug discovery and drug development is high in the North American region, increasing the demand for biochips to give a faster result. The rise in the cases of cancer in the area; therefore, there is a rise in the research in cancer, which is propelling the growth in the market. The government in the area promotes the use of biochips and increases the fund to develop the technology.
The cost of biochips is high and alternative technologies available for the biochips are the major restraints for the market growth. In addition, there is a lack of standardization and less awareness, which are considered the key challenges operating in the North American biochips market.
MARKET SEGMENTATION
This research report on the North American biochips market has been segmented and sub-segmented into the following categories.
-
DNA Chips
-
SNP Genotyping
- Genomics
- Agricultural Biotechnology
- Gene Expression
- Cancer Diagnosis & Treatment
- Drug Discovery
- Others
-
- Lab-On-A-Chip
- Clinical Diagnostics
- IVD & POC
- Drug Discovery
- Genomics
- Proteomics
- Protein Chips
- Expression Profiling
- High-Throughput Screening
- Proteomics
- Diagnostics
- Drug Discovery
North America Biochips Market - By End User
- Hospitals and Diagnostic Centers
- Biotechnology and Pharmaceutical Companies
- Academic & Research Institutes
North America Biochips Market - By Country
- The U.S.
- Canada
- Rest of North America
Based on the region, the North American region is currently dominating the global biochips market and accounted for the most significant share in the global market in 2024 due to technological advancements and a large pool of aging populace. As a result, the North American market leads the global market and is very modern, and is focused on innovating cost-effective chips.
The U.S. biochips market is estimated to lead the North American market throughout the forecast period. Biochips are used in the United States to monitor some medication in the geriatric population. Different institutes in the US are researching biochips, such as MIT. Biochips are used in various research on biomolecules in the United States. The government is funding biochip research, which is boosting market growth.
The Canadian biochips market had the second-highest market share in the North American region in 2024. Cancer is the significant burden of death in Canada, demanding a lot of research into cancer in Canada, and is estimated to increase the demand for biochips in this country. Furthermore, the government is promoting the use of biochips, which also favors the market.
KEY MARKET PLAYERS
A few promising companies leading the North American biochips market profiled in the report are Agilent Technologies Inc., Fluidigm Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., GE Healthcare, Cepheid Inc., Illumina Inc., and Thermo Fisher Scientific Inc.